论文部分内容阅读
药理噻氯匹定有广谱抗聚集的活性。在健康志愿者和有脑血管病、外周动脉病、缺血性心脏病或其它与血小板高聚作用有关疾病患者所得血小板的体外研究中,本品抑制胸苷二磷酸(ADP)引起的血小板聚集。这种作用在反复给药的第3～5天最大,停药10天还有作用。也有报道对其它血小板激动剂如花生四烯酸、胶原、凝血酶和血小板活化因子(RAF)-acether引起的体外血小板聚集亦有抑制作用,这种作用不是直接的,而是本品对这些激动剂在低浓度时释出ADP引起聚集的抑制作用的结果。本品与ADP和血小板相互作用引起的其它效果有:减少脑血管病患者血小板在粥
Pharmacological Ticlopidine has broad spectrum anti-aggregation activity. In vitro studies of healthy volunteers and platelets derived from patients with cerebrovascular disease, peripheral arterial disease, ischemic heart disease or other diseases associated with platelet hyperinflammation inhibit thymidine diphosphate (ADP) -induced platelet aggregation . This effect in the repeated administration of the first 3 to 5 days maximum withdrawal of 10 days there is a role. It has also been reported to inhibit platelet aggregation in vitro caused by other platelet agonists such as arachidonic acid, collagen, thrombin and platelet-activating factor (RAF) -acether, and this effect is not direct, but the effect of these agents on these agonisms The agent releases the inhibitory effect of ADP-induced aggregation at low concentrations. This product and ADP and platelet interactions caused by other effects are: reduce the incidence of cerebrovascular disease in patients with porridge